MedTrace Logo

The Optimization and Evaluation of the Extremism and Intolerance Curriculum for the Kingdom of Bahrain.

NCT05088694 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500

Last updated 2024-12-18

No results posted yet for this study

Summary

Researcher from UNC Greensboro have partnered with Prevention Strategies and key stakeholders from the Kingdom of Bahrain to conduct a study using the innovative, engineering-inspired methodological approach, the Multiphase Optimization Strategy (MOST), to optimize and evaluate the Peaceful Coexistence and Anti-Extremism middle and high school curricula. No other curriculum targeting tolerance and/or extremism has been optimized using the state-of-the-art MOST methodology. The overall goal of the project is that the optimized versions of Peaceful Coexistence and Anti-Extremism curricula will be used across the Kingdom of Bahrain and translated for use in other countries to combat the spread of extremism and intolerance. Additionally, the D.A.R.E. keepin' it REAL (kiR) and D.A.R.E. myPlaybook high school programs will be evaluated as part of the Peaceful Coexistence and Anti-Extremism evaluation.

Conditions

  • Norm, Social
  • Literacy
  • Resistance Skills
  • Beliefs About Consequences
  • Decision Making Skills
  • Empathy
  • Tolerance
  • Open Mindedness
  • Active Citizenship
  • Anti-extremism

Interventions

BEHAVIORAL

Peaceful Coexistence

The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance. The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior.

Sponsors & Collaborators

  • University of North Carolina, Greensboro

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088694 on ClinicalTrials.gov